CliniRx is a full service mid-size CRO that provides comprehensive end- to- end solutions for clinical studies. CliniRx’s services include Phase II –III and late Phase (Phase IV) across numerous therapeutic areas and specialties.These specialty areas include advanced therapies, geriatric population, pediatrics, and rare disease/orphan disease indications. CliniRx offers it’s services to Pharmaceutical, Biotechnology, and Medical Device companies. CliniRx’s rich talent available in-house is supplemented by independent external advisors, who can add value to our work. This is why, we have a network of external advisors and preferred partners. CliniRx conducts clinical trials in USA, Europe and Asia with offices located in India and USA. CliniRx is an affiliate of JK Organisation(www.jkorg.in), an over 125-years-old business conglomerate with leadership across multiple sectors and offices in 88 countries, many of which are public companies. The JK organisation is headquartered in India and has annual revenues of over $4.0 billion. CliniRx derives its values, financial stability and global mindset from JK Organisation enabling CliniRx to rapidly scale up to provide multiple services to Sponsor. CliniRx offers ICH-GCP compliant clinical trial services from Phase II – IV in key therapeutic areas. Multi-site investigator networks next to CliniRx’s well trained in-house team, seamlessly blends into a unique customized solution to match the needs and expectations of small, medium-size and large pharmaceutical, biotechnology and medical device sponsors. CliniRx’s expertise and high professional standards in the CNS area is demonstrated by an FDA audit for a Phase 3 study where CliniRx played lead CRO that concluded without any adverse findings; the study was accepted by the FDA and CHMP as a pivotal study and helped develop the first new chemical entity (NCE) approved for Parkinson’s Disease patients with motor fluctuations in the world in over a decade. CliniRx’s growing reputation in performing difficult, ground-breaking trials in the CNS area is demonstrated by its current involvement in multi-national, pivotal Phase II/III studies in Rare paediatric disorder where CliniRx has been entrusted to enrol approximately half of the global patients. CliniRx fully understands the complexities of clinical trials; therefore, offers a flexible model that helps to ensure that the Sponsor remain targeted with their plans in a timely, accurate and cost effective basis.